DRESS syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
Irfan Dotani (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{DRESS syndrome}} | {{DRESS syndrome}} | ||
{{CMG}}; {{AE}} {{YD}}; {{SSK}} | {{CMG}}; {{AE}} {{YD}}; {{SSK}} | ||
{{PleaseHelp}} | |||
==Overview== | ==Overview== | ||
Secondary preventive measures to avoid DRESS syndrome include avoidance of drug re-exposure, screening for cross-reacting agents using ''in vitro'' lymphocyte toxicity assays, and possibly desensitization techniques. | Secondary preventive measures to avoid DRESS syndrome include avoidance of drug re-exposure, screening for cross-reacting agents using ''in vitro'' lymphocyte toxicity assays, and possibly desensitization techniques. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Secondary preventive measures to avoid DRESS syndrome include the following:<ref name="pmid12771485">{{cite journal| author=Tas S, Simonart T| title=Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. | journal=Dermatology | year= 2003 | volume= 206 | issue= 4 | pages= 353-6 | pmid=12771485 | doi=69956 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12771485 }} </ref> | Secondary preventive measures to avoid DRESS syndrome include the following:<ref name="pmid12771485">{{cite journal| author=Tas S, Simonart T| title=Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. | journal=Dermatology | year= 2003 | volume= 206 | issue= 4 | pages= 353-6 | pmid=12771485 | doi=69956 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12771485 }} </ref> | ||
| Line 13: | Line 16: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
{{WS}} | |||
{{WH}} | |||
Latest revision as of 12:24, 20 July 2016
|
DRESS syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
DRESS syndrome On the Web |
|
American Roentgen Ray Society Images of DRESS syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Secondary preventive measures to avoid DRESS syndrome include avoidance of drug re-exposure, screening for cross-reacting agents using in vitro lymphocyte toxicity assays, and possibly desensitization techniques.
Secondary Prevention
Secondary preventive measures to avoid DRESS syndrome include the following:[1]
- Avoid re-exposure to drugs that have previously caused DRESS syndrome
- Screen for cross-reacting agents using in vitro lymphocyte toxicity assays
- Desensitization has not been reported to be effective in some case reports, but the true effectiveness of the desensitization has not been studied.[2]
References
- ↑ Tas S, Simonart T (2003). "Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update". Dermatology. 206 (4): 353–6. doi:69956 Check
|doi=value (help). PMID 12771485. - ↑ Moreno-Ancillo A, López-Serrano MC (1998). "Hypersensitivity reactions to drugs in HIV-infected patients. Allergic evaluation and desensitization". Clin Exp Allergy. 28 Suppl 4: 57–60. PMID 9761034.